Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Entrepreneurial pharmaceutical company, Ironwood Pharmaceuticals, Inc. (IRWD - Analyst Report) recently announced that it has completed the offering of $175 million Linaclotide PhaRMA 11% notes. The note will be due on or before June 15, 2024 with quarterly interest (11%) paying tenure beginning on June 15, 2013.

Principal amount of the notes will be paid quarterly from March 15, 2014. The amount of principal paid will be the difference between 7.5% of net US sales of Linzess (linaclotide) in the preceding quarter and accrued and unpaid interest on the notes.

The placement agent for this transaction was Morgan Stanley (MS - Analyst Report).

Ironwood Pharma intends to use the funds from the transaction to support the commercial launch of its lead product Linzess. The net proceeds will also be used to fund its research and development (R&D) expenses.

We note that Ironwood Pharma and partner Forest Laboratories, Inc. (FRX - Analyst Report) are co-promoting Linzess in the US. Linzess is approved by the US Food and Drug Administration (FDA) in August 2012 for the treatment (once-daily) of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

In the EU, approval came in November 2012 under the trade name Constella. Ironwood Pharma is collaborating with Almirall, S.A. in the EU for the drug. Ironwood Pharma is also working with its Japanese partner, Astellas Pharma (ALPMY) for the development of linaclotide in Japan and other Asian countries.

Our Recommendation

Currently, we have an Outperform long-term recommendation on Ironwood Pharma. The company carries a Zacks #1 Rank (Strong Buy) in the short run.

Other Zacks #1 Rank stocks include Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report) and Astellas Pharma.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 33.21 +7.92%
E COMMERCE C DANG 12.50 +4.52%
E*TRADE FINA ETFC 21.23 +4.25%
BIO PATH HOL BPTH 2.87 +4.18%
DIXIE GROUP DXYN 14.58 +3.70%